Sofinnova Ventures leads $57m series-B for Nucana
US-based Sofinnova Ventures has a led a $57m series-B round for biopharmaceutical company Nucana, alongside existing European investors.
Paris-based Sofinnova Partners also joined the round alongside existing investors Morningside Ventures, Alida Capital and the Scottish Investment Bank.
The capital will be used to expand the clinical trial for Nucana's cancer treatment medicine, Acelarin, and the introduction of three additional new products into the clinic.
Company
Nucana is a biopharmaceutical company based in Edinburgh. It has developed ProTide technology, which creates compounds that bypass resistance mechanisms associated with some cancer medicines. It has also previously used the technology in the treatment of HCV and HIV.
People
Hugh S Griffith is CEO and co-founder of Nucana. James Healy is a general partner at Sofinnova Ventures and will take a seat on the board along with Gerald Chan, co-founder and chairman of Morningside. Rafaèle Tordjman is a managing partner at Sofinnova Partners and currently has a seat on the board at Nucana.
More on UK / Ireland
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater